Consequently, BRAF is an attractive validated therapeutic target in melanoma, and several BRAF inhibitors are currently under development and in clinical trials5 and we have previously described type II BRAF inhibitors, targeting the inactive conformation of BRAF.6,7. This evidence concerns the gene BRAF and melanoma.